Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial

被引：6
|
作者：
Richardson, Paul G. [1 ]
Sandhu, Irwindeep [2 ]
Hofmeister, Craig C. [3 ]
Orlowski, Robert Z. [4 ]
White, Darrell [5 ,6 ]
Belotti, Angelo [7 ]
Hansen, Charlotte Toftmann [8 ]
Raje, Noopur S. [9 ]
Chow, Tracy T. [10 ]
Zhou, Zehua [10 ]
Civardi, Tiziana [11 ]
Koo, Phillip [10 ]
Zhu, Yue [10 ]
Katz, Jessica [10 ]
Oriol, Albert [12 ,13 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Cross Canc Inst, Edmonton, AB, Canada
[3] Winship Canc Inst Emory Univ, Atlanta, GA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA
[5] Dalhousie Univ, Halifax, NS, Canada
[6] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[7] ASST Spedali Civili Brescia, Dept Hematol, Brescia, Italy
[8] Odense Univ Hosp, Odense, Denmark
[9] Massachusetts Gen Hosp, Boston, MA USA
[10] Bristol Myers Squibb, Princeton, NJ USA
[11] Bristol Myers Squibb Co, Celgene Int Sarl, Boudry, Switzerland
[12] Hosp Germans Trias i Pujol, Catalan Inst Oncol, Badalona, Spain
[13] Hosp Germans Trias i Pujol, Josep Carreras Inst, Badalona, Spain
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-174443
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial
    Oriol, Albert
    Sandhu, Irwindeep
    Raab, Marc
    White, Darrell
    LeBlanc, Richard
    Raje, Noopur
    Ocio, Enrique
    Perrot, Aurore
    Facon, Thierry
    Rodriguez, Cesar
    Waesch, Ralph
    Amatangelo, Michael
    Zhou, Zehua
    Wang, Yue
    Civardi, Tiziana
    Koo, Philip
    Maciag, Paulo
    Zhu, Daniel
    Katz, Jessica
    Richardson, Paul
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S31 - S31
  • [2] Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial
    Orlowski, Robert Z.
    Bahlis, Nizar J.
    Quach, Hang
    Popat, Rakesh
    Lonial, Sagar
    Kim, Kihyun
    Mateos, Maria-Victoria
    Pawlyn, Charlotte
    Ramasamy, Karthik
    Martinez-Lopez, Joaquin
    Casas-Aviles, Ignacio
    Spirli, Alessia
    Gong, Jing
    Amatangelo, Michael
    Katz, Jessica
    Maciag, Paulo
    Peluso, Teresa
    Richardson, Paul G.
    Trudel, Suzanne
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S492 - S493
  • [3] Mezigdomide (MEZI; CC-92480) in Combination with Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Raab, M. S.
    Richardson, P. G.
    Sandhu, I
    Oriol, A.
    White, D.
    LeBlanc, R.
    Perrot, A.
    Ocio, E. M.
    Raje, N.
    Hansen, C. Toftmann
    Zhou, Z.
    Civardi, T.
    Katz, J.
    Peluso, T.
    Dimopoulos, M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 56 - 56
  • [4] Mezigdomide (MEZI) monotherapy in relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-001 trial
    Goldsmith, Scott
    Oriol, Albert
    Anttila, Pekka
    Bahlis, Nizar
    Berdeja, Jesus
    Cowan, Andrew
    Dimopoulos, Meletios
    Foster, Laahn
    Hillengass, Jens
    Louzada, Martha
    Wu, Ka Lung
    Chow, Tracy
    Chen, Wencong
    Wang, Yue
    Spirli, Alessia
    Koo, Phillip
    Maciag, Paulo
    Zhu, Daniel
    Katz, Jessica
    Richardson, Paul
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S181 - S182
  • [5] Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Richardson, Paul
    Sandhu, Irwindeep
    Oriol, Albert
    Raab, Marc S.
    White, Darrell
    LeBlanc, Richard
    Perrot, Aurore
    Ocio, Enrique
    Raje, Noopur
    Hansen, Charlotte Toftmann
    Zhou, Zehua
    Civardi, Tiziana
    Ghiddi, Alessandro
    Katz, Jessica
    Peluso, Teresa
    Dimopoulos, Meletios A.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S33 - S33
  • [6] Initial results of phase 1/2 study CC-92480-MM-002 onCELMoD CC-92480 in combination with bortezomib (BORT)and dexamethasone (DEX) in patients with relapsed /refractory multiple myeloma (RRMM)
    Raab, M. -S.
    Richardson, P. G.
    Ocio, E. M.
    Raje, N.
    Gregory, T.
    White, D.
    Oriol, A.
    Sandhu, I.
    LeBlanc, R.
    Rodriguez Valdes, C.
    Trudel, S.
    Waesch, R.
    Perrot, A.
    Bahlis, N. J.
    Zhou, Z.
    Lamba, M.
    Amatangelo, M.
    Civardi, T.
    Katz, J.
    Maciag, P.
    Peluso, T.
    Dimopoulos, M. A.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 86 - 86
  • [7] Preliminary results from phase 2 of CC-92480-MM-001: Mezigdomide plus dexamethasone in relapsed/refractory multiple myeloma (RRMM)
    Popat, Rakesh
    Richardson, Paul G.
    Trudel, Suzanne
    Quach, Hang
    Lonial, Sagar
    Orlowski, Robert Z.
    Kim, Kihyun
    Mateos, Maria-Victoria
    Pawlyn, Charlotte
    Ramasamy, Karthik
    Martinez-Lopez, Joaquin
    Casas-Aviles, Ignacio
    Spirli, Alessia
    Gong, Jing
    Amatangelo, Michael
    Katz, Jessica
    Maciag, Paulo
    Peluso, Teresa
    Bahlis, Nizar J.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 66 - 67
  • [8] Melflufen and dexamethasone (dex) plus bortezomib (BTZ) or daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (OP-104)
    Pour, Ludek
    Efebera, Yvonne
    Granell, Miquel
    Hajek, Roman
    Oriol, Albert
    Delaunay, Jacques
    Le Du, Katell
    Eveillard, Jean-Richard
    Karlin, Lionel
    Maisnar, Vladimir
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Moreb, Jan
    Ribrag, Vincent
    Richardson, Paul G.
    Straub, Jan
    Byrne, Catriona
    Jacques, Christian
    Zubair, Hanan
    Ocio, Enrique
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [9] Durvalumab (DURVA) plus daratumumab (DARA) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).
    Richardson, Paul G.
    Bensinger, William
    Weisel, Katja C.
    Boyd, Kevin
    Ramasamy, Karthik
    Gonzalez, Esther
    Favre-Kontula, Linda
    Peluso, Teresa
    Sternas, Lars Axel
    Di Casoli, Carl
    Zaki, Mohamed H.
    Facon, Thierry
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002
    Richardson, Paul G.
    Ocio, Enrique
    Raje, Noopur S.
    Gregory, Tara
    White, Darrell
    Oriol, Albert
    Sandhu, Irwindeep
    Raab, Marc-Steffen
    Le Blanc, Richard
    Rodriguez, Cesar
    Trudel, Suzanne
    Waesch, Ralph
    Perrot, Aurore
    Bahlis, Nizar J.
    Zhou, Zehua
    Lamba, Manisha
    Amatangelo, Michael
    Civardi, Tiziana
    Katz, Jessica
    Aciag, Paulo M.
    Peluso, Teresa
    Dimopoulos, Meletios A.
    [J]. BLOOD, 2021, 138
12345